Ursula Matulonis, MD

Ursula A. Matulonis, MD is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She co-leads the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer.

Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, and combination trials for ovarian cancer in the United States and internationally. Dr. Matulonis serves on the Massachusetts Ovarian Cancer Task Force, chairs the Gyn subcommittee of the Alliance cooperative group, and the Scientific Advisory Board for the Ovarian Cancer Research Alliance, the Rivkin Foundation, the Clearity Foundation, and Overcome. She has received the Dana-Farber Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler "Extra Mile" Award, the Clearity Foundation award, the Zakim Award at Dana-Farber for patient advocacy, and recently in 2020, the Albany Medical College Alumni Association Distinguished Alumna Award. She has been named one of Boston's Best Physicians in Medical Oncology by Boston Magazine numerous times. Dr. Matulonis is also a recipient of grant funding from the Breast Cancer Research Foundation examining differences between ovarian cancer, endometrial cancer and breast cancer.

After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at Dana-Farber Cancer Institute in Boston, MA.

View full profile